Valneva Charts a Leaner Course After Disappointing Start to 2025, Awaiting Pfizer's Lyme Vaccine Filing

Investors breathed a cautious sigh of relief this week as Valneva unveiled a sweeping cost-cutting plan alongside a lower financial outlook. The French vaccine developer is trimming 10 to 15 percent of its global workforce and targeting a roughly one-third reduction in operating expenses versus last year, a response to travel vaccine demand that has come off the boil amid geopolitical tensions. The stock jumped 15 percent on the week to €2.66, though it remains down about 30 percent since the start of the year.

The restructuring accompanies a downward revision to the company’s full-year targets. Valneva now expects product sales of between €135 million and €150 million, a material comedown from earlier guidance. On an all-in basis including other revenue streams, total revenues are forecast to fall between €155 million and €170 million. The caution stems largely from a weak first quarter, when product sales shrank to €30.9 million from roughly €49 million a year earlier.

The first-quarter slide was driven by several factors: the phasing out of third-party distribution deals, a shift in delivery schedules for the U.S. military’s Ixiaro order book, and a broader softness in travel vaccination demand. Ixiaro sales alone came in at €20.2 million. Unfavourable currency movements added to the pain, pushing the net loss to over €32 million. Despite the red ink, the balance sheet remains manageable: cash and equivalents stood at roughly €105 million at the end of March, supplemented by a capital increase completed in April.

Should investors sell immediately? Or is it worth buying Valneva?

Management’s focus is now fixed on the pipeline, with the Lyme disease vaccine candidate VLA15 taking centre stage. Partner Pfizer is pressing ahead with regulatory filings despite the programme having missed a technical primary endpoint in Phase 3 – efficacy came in above 70 percent, but the lower bound of the statistical confidence interval slipped below a predefined threshold. Pfizer still plans to submit approval applications to the FDA and EMA in the second half of 2026. Until then, Valneva says it is adequately funded to see the process through.

A more immediate bright spot is emerging in Brazil. The local health authority ANVISA granted approval for the Chikungunya vaccine IXCHIQ to be produced domestically by the Instituto Butantan, a move that opens the door to integration into the country’s public health system. Already 30,000 adults have received the jab as part of a pilot campaign.

Looking ahead, the next catalyst for the stock could come from a less heralded project. Mid-year, Valneva expects to release Phase 2 data on its Shigella vaccine candidate, aimed at severe diarrhoeal disease. A positive readout would shift some attention away from the current restructuring narrative and back toward the longer-term promise of the pipeline. For now, however, the share price remains well below its 200-day moving average of €3.89, underscoring how much ground has to be made up.

Ad

Valneva Stock: New Analysis - 14 May

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69329317 |